Immunogenicity of recombinant hepatitis B vaccine in treatment-naïve and treatment-experienced chronic hepatitis C patients: The effect of pegylated interferon plus ribavirin treatment

World Journal of Gastroenterology

Volumn 12, Issue 27, 2006, Pages 4420-4424

  Elefsiniotis, Ioannis S ^a,b,c   Vezali, Elena ^a   Kamposioras, Konstantinos ^a   Pantazis, Konstantinos D ^b   Tontorova, Radostina ^a   Ketikoglou, Ioannis ^a   Moulakakis, Antonios ^a   Saroglou, George ^b  

^a HIPPOKRATION HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c NONE   (Greece)

Author keywords

Chronic hepatitis C; Hepatitis B vaccine; Interferon; Ribavirin

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; PEGINTERFERON ALPHA2A; RECOMBINANT HEPATITIS B VACCINE; RIBAVIRIN; VIRUS RNA;

ADULT; ANALYSIS OF VARIANCE; ANTIBODY RESPONSE; ARTICLE; CHI SQUARE TEST; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; INTRAVENOUS DRUG ABUSE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POSTTRANSFUSION HEPATITIS; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR; SEROCONVERSION; STUDENT T TEST; TREATMENT OUTCOME; VACCINATION; VIRUS GENOME;

EID: 33746897757     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i27.4420     Document Type: Article

References (24)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745
2. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26: 62S-65S
3. Delage G, Infante-Rivard C, Chiavetta JA, Willems B, Pi D, Fast M. Risk factors for acquisition of hepatitis C virus infection in blood donors: results of a case-control study. Gastroenterology 1999; 116: 893-899
4. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997; 336: 196-204
5. Encke J, zu Putlitz J, Wands JR. DNA vaccines. Intervirology 1999; 42: 117-124
6. Coates RA, Halliday ML, Rankin JG, Stewart JD, Bristow NJ, Granero R, West DJ. Viral Hepatitis and Liver Disease. New York: AR Liss, 1998: 1038-1042
7. Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F, Tran van Nhieu J, Seigneurin JM, Buffet C, Dhumeaux D. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998; 28: 27-33
8. Crespo J, Lozano JL, Carte B, de las Heras B, de la Cruz F, Pons-Romero F. Viral replication in patients with concomitant hepatitis B and C virus infections. Eur J Clin Microbiol Infect Dis 1997; 16: 445-451
9. Pontisso P, Ruvoletto MG, Fattovich G, Chemello L, Gallorini A, Ruol A, Alberti A. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology 1993; 105: 1529-1533
10. National Institutes of Health (NIH) Consensus Development Conference Panel Statement. Management of hepatitis C. Hepatology 1997; suppl 26: S2-10
11. Siddiqui F, Mutchnick M, Kinzie J, Peleman R, Naylor P, Ehrinpreis M. Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed hepatitis C: implications for vaccination strategy. Am J Gastroenterol 2001; 96: 858-863
12. Leroy V, Bourliere M, Durand M, Abergel A, Tran A, Baud M, Botta-Fridlund D, Gerolami A, Ouzan D, Halfon P, Zarski JP. The antibody response to hepatitis B virus vaccination is negatively influenced by the hepatitis C virus viral load in patients with chronic hepatitis C: a case-control study. Eur J Gastroenterol Hepatol 2002; 14: 485-489
13. Wiedmann M, Liebert UG, Oesen U, Porst H, Wiese M, Schroeder S, Halm U, Mossner J, Berr F. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology 2000; 31: 230-234
14. Idilman R, De MN, Colantoni A, Nadir A, Van Thiel DH. The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C. Am J Gastroenterol 2002; 97: 435-439
15. Lee SD, Chan CY, Yu MI, Lu RH, Chang FY, Lo KJ. Hepatitis B vaccination in patients with chronic hepatitis C. J Med Virol 1999; 59: 463-468
16. Chlabicz S, Grzeszczuk A, Lapinski TW. Hepatitis B vaccine immunogenicity in patients with chronic HCV infection at one year follow-up: the effect of interferon-alpha therapy. Med Sci Monit 2002; 8: CR379-383
17. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699
18. Rosman AS, Lieber CS. Improving the response to hepatitis B vaccine. Infect Med 1999; 16: 205-210
19. Luo KX, Wang LP, Nie J, Jiang S. Is nonresponsiveness to hepatitis B vaccine due to latent hepatitis B virus infection? J Infect Dis 1992; 165: 777-778
20. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-26
21. Van Thiel DH. Vaccination of patients with liver disease: who, when, and how. Liver Transpl Surg 1998; 4: 185-187
22. Lerat H, Rumin S, Habersetzer F, Berby F, Trabaud MA, Trepo C, Inchauspe G. In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood 1998; 91: 3841-3849
23. de Mattos AA, Gomes EB, Tovo CV, Alexandre CO, Remiao JO. Hepatitis B vaccine efficacy in patients with chronic liver disease by hepatitis C virus. Arq Gastroenterol 2004; 41: 180-184
24. Goldwater PN. Randomized comparative trial of interferon-alpha versus placebo in hepatitis B vaccine non-responders and hyporesponders. Vaccine 1994; 12: 410-414